Five-year results of the prospective Phase III WSG PlanB trial confirm prognostic impact of 21-Gene Recurrence Score in high-risk HR+/HER2− early breast cancer (EBC) patients with 1-3 involved lymph nodes. (March 2017) - Gluz, O.; Nitz, U.; Christgen, M.; Kates, R.; Clemens, M.; Nuding, B.; Shak, S.; Würstlein, R.; Kreipe, H.; Harbeck, N.